Insmed Incorporated Forecast, price target & analysts
Insmed Incorporated Target price 2025 - Analyst rating & recommendation
Insmed Incorporated Classifications & Recommendation:
Insmed Incorporated Price Target
| Target Price | $97.13 |
| Price | $79.05 |
| Potential |
22.87%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Insmed Incorporated 2026 .
The average Insmed Incorporated target price is $97.13.
This is
22.87%
register free of charge
$108.00
36.62%
register free of charge
$89.00
12.59%
register free of charge
|
|
| A rating was issued by 18 analysts: 18 Analysts recommend Insmed Incorporated to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2026 of
22.87%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 363.71 | 471.42 |
| 19.17% | 29.61% | |
| EBITDA Margin | -213.24% | -192.92% |
| 2.91% | 9.53% | |
| Net Margin | -274.71% | -194.95% |
| 12.47% | 29.03% |
16 Analysts have issued a sales forecast Insmed Incorporated 2025 . The average Insmed Incorporated sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Insmed Incorporated EBITDA forecast 2025. The average Insmed Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Insmed Incorporated Analysts have issued a net profit forecast 2025. The average Insmed Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.57 | -5.12 |
| 4.31% | 8.08% | |
| P/E | negative | |
| EV/Sales | 30.10 |
16 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Insmed Incorporated stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Insmed Incorporated...
Current Insmed Incorporated Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital | Locked ➜ Locked | Locked | Feb 25 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Feb 25 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 24 2025 |
| Stifel | Locked ➜ Locked | Locked | Feb 21 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 21 2025 |
| Truist Securities | Locked ➜ Locked | Locked | Feb 21 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Feb 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital: Locked ➜ Locked
|
Feb 25 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Feb 25 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Stifel: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Feb 20 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
